Immune dysregulation in chronic lymphocytic leukemia (CLL) contributes to a high rate of infections and morbidity. The Bruton tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib mark major breakthroughs in the treatment of CLL, however many patients require long-term therapy with these agents. Despite receiving effective therapy for CLL, patients on BTK inhibitors remain immunocompromised and at risk of infectious complications. We previously reported that treatment of CLL with ibrutinib leads to partial reconstitution of humoral immunity and fewer infections during the first two years of therapy. It is currently unclear whether the positive effects of ibrutinib on the immune system are sustained during long-term therapy. Acalabrutinib is a newer, more selective BTK inhibitor than ibrutinib; however a detailed evaluation of the immunologic impact of acalabrutinib therapy is lacking. Herein, utilizing two independent trials, we assessed the immunological effects and infectious risk of ibrutinib and acalabrutinib treatment in patients with CLL.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482427PMC
http://dx.doi.org/10.1080/10428194.2020.1772477DOI Listing

Publication Analysis

Top Keywords

reconstitution humoral
8
humoral immunity
8
chronic lymphocytic
8
lymphocytic leukemia
8
bruton tyrosine
8
tyrosine kinase
8
btk inhibitors
8
ibrutinib acalabrutinib
8
treatment cll
8
cll patients
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!